CRS Revenue and Competitors

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • CRS's estimated annual revenue is currently $7.2M per year.(i)
  • CRS's estimated revenue per employee is $168,000

Employee Data

  • CRS has 43 Employees.(i)
  • CRS grew their employee count by 10% last year.

CRS's People

NameTitleEmail/Phone
1
Chief Financial & Administrative OfficerReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Director, PolicyReveal Email/Phone
4
Director, Technical ProjectsReveal Email/Phone
5
Executive DirectorReveal Email/Phone
6
Director, PolicyReveal Email/Phone
7
Senior Manager, Standards and Technical AssistanceReveal Email/Phone
8
Manager, Events and EducationReveal Email/Phone
9
Senior Manager, Program OutreachReveal Email/Phone
10
ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M31-11%N/AN/A
#2
$5.5M33-13%N/AN/A
#3
$449.5M149741%$5.6MN/A
#4
$4.3M2971%N/AN/A
#5
$94.2M359-11%$591KN/A
#6
$45.2M2004%N/AN/A
#7
$80.9M3087%N/AN/A
#8
$3.5M244%N/AN/A
#9
$7.2M4310%N/AN/A
#10
$3.8M26-26%N/AN/A
Add Company

What Is CRS?

Center for Resource Solutions (CRS) creates policy and market solutions to advance sustainable energy. We're a national nonprofit with global impact. CRS brings forth expert responses to climate change issues with the speed and effectiveness necessary to provide real-time solutions. Our leadership through collaboration and environmental innovation builds policies and consumer-protection mechanisms in renewable energy, greenhouse gas reductions, and energy efficiency that foster healthy and sustained growth in national and international markets.

keywords:N/A

N/A

Total Funding

43

Number of Employees

$7.2M

Revenue (est)

10%

Employee Growth %

N/A

Valuation

N/A

Accelerator

CRS News

2022-04-20 - Surveyed Patients Identify Unmet Needs in CRS With Nasal Polyps

Patients with chronic rhinosinusitis (CRS) with nasal polyps identified several unmet needs regarding their condition, particularly a lack...

2022-04-17 - SEC Settles with 12 Firms for Incomplete CRS Obligations

(See SEC Staff Statement Highlights Need for Form CRS Disclosure Improvements, available here.) The SEC's press release announcing the...

2022-04-06 - Can Anakinra Spare Tocilizumab in Management of CAR T-Cell CRS?

Finding an effective alternative or adjunctive treatment for CRS is critical, given that CRS is a common and potentially fatal complication...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.7M43-23%$4.2M
#2
$11.1M43-2%N/A
#3
$8.6M4316%N/A
#4
$5.2M43N/AN/A
#5
$8.4M4313%N/A